Clinical Trial Update: Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of a vaccine therapy using tumor-specific mutated VHL peptides in adults with renal cell carcinoma was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• VHL peptide vaccine (tumor-specific mutated VHL peptides)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2012-06-14